What type of study is this?

Severe delayed coagulopathy caused by cefoperazone/sulbactam: A case report

View Full Paper

Ask AI

Bookmark

Authors

Case report reveals prolonged clotting times in patient treated with cefoperazone/sulbactam, suggesting coagulopathy risk.

The patient experienced severe coagulopathy after 23 days on cefoperazone/sulbactam, leading to significant bleeding risk.
Prothrombin time improved by 88.4% after vitamin K treatment on day 28, indicating the potential for recovery.
The Naranjo score of 5 implies a strong likelihood of adverse effects linked to cefoperazone/sulbactam administration.
Monitoring for coagulopathy is crucial in patients treated with cefoperazone/sulbactam due to their heightened bleeding risk.

Sun et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark